Review evidence on sequencing of KRAS inhibitors after progression on the initial treatment.
NKTR-255 Shows Promise for Reversing Radiation-Induced Lymphopenia in NSCLC
NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung cancer, with a safety profile similar to earlier studies.
Read More
Lisberg Discusses Dato-DXd's Role in Advanced Lung Cancer Care
In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.
Listen
Brigatinib Plus Local Consolidative Therapy Shows Promise in ALK+ NSCLC
During a Case-Based Roundtable® event, Chul Kim, MD, discussed the ALTA-1 trial and BRIGHTSTAR trials of brigatinib in ALK+ lung cancer in the first article of a 2-part series.
Strategies for Neoadjuvant NSCLC Treatment
In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.
First Patients Dosed in New Phase 3 Trials of Dato-DXd in NSCLC
Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.
Exploring the Perioperative Treatment Setting in Lung Cancer
An expert addressed the emerging role of immune checkpoint inhibitors in the perioperative space based on findings from the CheckMate 816, IMpower010, PEARLS, and ADAURA trials.